Valeant seriously considering the sale of neuro assets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat
October 20, 2015 10:22 AM EDTJefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following the company's 3Q results. VRX reported revenues of $2.79B vs the Street's $2.78B. EPS was reported at $2.74 vs the Street's $2.72.
Analyst David Steinberg... More
Mizuho Securities Remains Neutral After Valeant Pharma (VRX) Reports 2c EPS Beat
October 20, 2015 6:46 AM EDTMizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings report. Revenues of $2.80B beat consensus estimates of $2.79B and EPS of $2.74 came in $0.02 higher. Management raised full year revenue guidance to $11.0-$11.2B and... More
BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance
October 20, 2015 6:42 AM EDTBMO Capital maintained an Outperform rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $265.00 (from $273.00), following the company's 3Q15 earnings results. VRX beat expectations for the quarter, however, the results showed that the legacy business had underperformed.
Analyst Alex Arfaei... More
